Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8881442rdf:typepubmed:Citationlld:pubmed
pubmed-article:8881442lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:8881442lifeskim:mentionsumls-concept:C0031117lld:lifeskim
pubmed-article:8881442lifeskim:mentionsumls-concept:C0020861lld:lifeskim
pubmed-article:8881442lifeskim:mentionsumls-concept:C1136085lld:lifeskim
pubmed-article:8881442lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:8881442pubmed:issue5lld:pubmed
pubmed-article:8881442pubmed:dateCreated1996-12-12lld:pubmed
pubmed-article:8881442pubmed:abstractTextEffective therapy of peripheral neuropathies associated with a serum monoclonal IgM remains difficult. Chemotherapy with Chlorambucil yielded a moderate improvement in only a third of the patients. No additional benefit was given with plasma exchanges. However they can be used in case of rapid worsening or of motor of the disease. Intravenous immunoglobulins were not effective in a recent prospective controled study. However, in this study a-interferon yielded improvement in more than half of the patients. These results have to be confirmed and mechanism of action of a-interferon needs to be elucidated.lld:pubmed
pubmed-article:8881442pubmed:languagefrelld:pubmed
pubmed-article:8881442pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8881442pubmed:citationSubsetIMlld:pubmed
pubmed-article:8881442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8881442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8881442pubmed:statusMEDLINElld:pubmed
pubmed-article:8881442pubmed:monthMaylld:pubmed
pubmed-article:8881442pubmed:issn0035-3787lld:pubmed
pubmed-article:8881442pubmed:authorpubmed-author:OksenhendlerE...lld:pubmed
pubmed-article:8881442pubmed:authorpubmed-author:MarietteXXlld:pubmed
pubmed-article:8881442pubmed:issnTypePrintlld:pubmed
pubmed-article:8881442pubmed:volume152lld:pubmed
pubmed-article:8881442pubmed:ownerNLMlld:pubmed
pubmed-article:8881442pubmed:authorsCompleteYlld:pubmed
pubmed-article:8881442pubmed:pagination413-6lld:pubmed
pubmed-article:8881442pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8881442pubmed:meshHeadingpubmed-meshheading:8881442-...lld:pubmed
pubmed-article:8881442pubmed:meshHeadingpubmed-meshheading:8881442-...lld:pubmed
pubmed-article:8881442pubmed:meshHeadingpubmed-meshheading:8881442-...lld:pubmed
pubmed-article:8881442pubmed:meshHeadingpubmed-meshheading:8881442-...lld:pubmed
pubmed-article:8881442pubmed:meshHeadingpubmed-meshheading:8881442-...lld:pubmed
pubmed-article:8881442pubmed:year1996lld:pubmed
pubmed-article:8881442pubmed:articleTitle[Treatment of peripheral neuropathies associated with IgM anti-myelin monoclonal gammopathy].lld:pubmed
pubmed-article:8881442pubmed:affiliationService d'Immuno-Hématologie, Hôpital Saint-Louis, Paris.lld:pubmed
pubmed-article:8881442pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8881442pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:8881442pubmed:publicationTypeReviewlld:pubmed